Unraveling Parkinson's: The Power of Neuroimaging Biomarkers

Parkinson’s disease research is limited by late clinical diagnosis and the lack of objective measures in early stages. Neuroimaging biomarkers provide quantitative insight into brain changes that occur before motor symptoms appear—supporting earlier characterization, disease monitoring, and more reliable clinical trial outcomes.

This whitepaper explores how MRI- and PET-based biomarkers are being used in Parkinson’s disease research, the challenges of implementing them at scale, and best practices for integrating imaging biomarkers into multi-site studies.

👉 Download the whitepaper to understand the role of neuroimaging biomarkers in Parkinson’s disease research and clinical trials.